Related Experiment Video
Updated: Jun 25, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Intensive Combination LDL-Lowering Therapy in a Patient With Homozygous Familial Hypercholesterolemia
Hayato Tada1, Hirofumi Okada1, Masa-Aki Kawashiri1
1Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Insights
A boy with severe familial hypercholesterolemia resistant to standard treatments showed significant LDL cholesterol reduction and plaque regression with novel therapies, including lomitapide and evinacumab.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Familial hypercholesterolemia (FH) is a genetic disorder causing extremely high LDL cholesterol.
- Homozygous FH (HoFH) is rare and presents a significant challenge in lipid management.
- Standard lipid-lowering therapies are often insufficient for HoFH patients.
Observation:
- A young boy with HoFH exhibited resistance to statins and ezetimibe.
- Lipoprotein apheresis was initiated at 6 years of age.
- Progressive atherosclerosis was evident, including carotid plaque.
Findings:
- Combination therapy with lomitapide and evinacumab significantly reduced low-density lipoprotein cholesterol (LDL-C) levels.
- The addition of these novel agents led to a notable regression of carotid plaque.
- Treatment demonstrated efficacy in a statin- and ezetimibe-resistant HoFH case.
Implications:
- Lomitapide and evinacumab offer a promising therapeutic strategy for severe, refractory HoFH.
- Early intervention with advanced therapies may halt or reverse atherosclerotic progression in HoFH.
- This case highlights the potential of targeted therapies in managing genetic lipid disorders.
Abstract:
We present a young boy with a diagnosis of homozygous familial hypercholesterolemia who presented with statin and ezetimibe resistance. The patient received lipoprotein apheresis at 6 years of age. His low-density lipoprotein cholesterol levels significantly were reduced by adding lomitapide and evinacumab, and his carotid plaque started to regress.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipids: Dietary Sources and Requirements
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

